ArticleThe Iowa orthopaedic journal1999
Osteoporosis: the increasing role of the orthopaedist.
Article in The Iowa orthopaedic journal, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Determination of the Combined Effects of Asian Herbal Medicine with Calcium and/or Vitamin D Supplements on Bone Mineral Density in Primary Osteoporosis: A Systematic Review and Meta-Analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Pooled it
- Using a Polygenic Score to Predict the Risk of Developing Primary Osteoporosis.International journal of molecular sciences · 2022Pooled it
- Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.Alimentary pharmacology & therapeutics · 2024Trial
- Longitudinal associations between changes in bone mechanical strength and fracture risk estimated by μFRAC.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Disuse Bone Loss After Spinal Cord Injury: Scope and Challenges, Potential Mechanisms, Treatment, and Future Directions.Journal of the Endocrine Society · 2026Review
- The Role of Osteoporosis in Spine Surgery and Current Management Strategies: A Review.Current osteoporosis reports · 2025Review
- Postbiotics: A Promising Approach to Combat Age-Related Diseases.Life (Basel, Switzerland) · 2025Review
- The Role of Osteoporosis in Total Hip Arthroplasty Periprosthetic Fractures and Current Management Strategies: a Review.Current osteoporosis reports · 2025Review
- Machine Learning Models for Frailty Classification of Older Adults in Northern Thailand: Model Development and Validation Study.JMIR aging · 2025Article
- Choose your mother wisely: the familial resemblance of bone adaptation.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Radiomic-based biomarkers: Transforming age and body composition metrics into personalized age-informed indices.Clinical and translational science · 2024Review
- Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.Nature aging · 2024Review
- Identification of Osteosarcopenia by High-Resolution Peripheral Quantitative Computed Tomography.Journal of personalized medicine · 2024Article
- An in silico approach to elucidate the pathways leading to primary osteoporosis: age-related vs. postmenopausal.Biomechanics and modeling in mechanobiology · 2024Article
- Protective Effects of the Postbiotic Lactobacillus plantarum MD35 on Bone Loss in an Ovariectomized Mice Model.Probiotics and antimicrobial proteins · 2024Article
- Article
- Exploring epigenetic strategies for the treatment of osteoporosis.Molecular biology reports · 2024Review
- Molecularly Imprinted Polymers: Shaping the Future of Early-Stage Bone Loss Detection-A Review.ACS omega · 2024Review
- Effects of stepwise administration of osteoprotegerin and parathyroid hormone-related peptide DNA vectors on bone formation in ovariectomized rat model.Scientific reports · 2024Article
- Japanese quails (Frontiers in physiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is an ever-increasing problem as our population ages. However, it is also to a large extent a preventable problem. The orthopaedist now has the ability to determine bone mass, the rate of turnover, and the fracture risk. Skeletal bone mass can be evaluated with DXA; the rate of bone resorption can be determined by assessment of collagen-degradation urinary products; and the weight status, fracture history, and history of smoking can be used to predict the fracture risk in individual patients. The orthopaedic physician also needs to take an active role in advising their younger patients about achieving peak bone mass. All individuals should follow a program that includes adequate calcium replacement, 400 to 800 units of vitamin D, appropriate exercise, avoidance of significant weight loss, and cessation of smoking. At menopause, women should evaluate their risk factors and consider the use of estrogen not only for its skeletal benefits but also for its nonosseous effects. In patients with contraindications or an aversion to hormone therapy, bone densitometry should be performed to determine risks before expensive nonhormonal treatment is initiated. Additional studies such as measurement of collagen degradation products will help establish whether the patient's resorptive rate is high or stable. If the bone mass is 2.5 SDs below normal peak or if there is an increase in resorption, use of either estrogen, bisphosphontes, or calcitonin may be appropriate. If there is evidence of low-turnover osteoporosis with decreased osteoblast formation, sodium fluoride should be considered. Two thirds of the cost of osteoporosis in the United States is due to hip fractures. The orthopaedist is the primary physician who comes in contact with these fracture patients. It is therefore his or her responsibility to become knowledgeable about the treatment and prevention of osteoporosis. The bisphosphonates, hormones, and calcitonin provide predictable restoration of bone mass and significantly decrease the rate of osteoporotic fractures.
Indexed as
Identifiers
10847516PMC1888612W1459075092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.